Journal: Acta Neuropathologica Communications

Article Title: Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3 - TACC3 fusions

doi: 10.1186/s40478-020-01058-6

Figure Lengend Snippet: Kaplan-Meier analysis of overall survival stratified by FGFR3 - TACC3 fusion ( a ) and MGMT promoter hypermethylation ( b ) status. Note : Overall survival was defined as the time from initial diagnostic biopsy until the time of death due to any cause. Two-sided p values for difference were calculated using the log-rank test

Article Snippet: Reported MGMT promoter hypermethylation status, typically determined by pyrosequencing, was extracted from the electronic medical record for those patients who did not undergo methylation analysis on the Infinium platform [ ].

Techniques: Diagnostic Assay

Journal: Journal of Neuro-Oncology

Article Title: MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing

doi: 10.1007/s11060-026-05633-0

Figure Lengend Snippet: Flowchart of patient selection. MGMTpm, MGMT promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR

Article Snippet: A third option is to establish a cut-off based on outcome, such as in the study by Quillien where the Pyromark MGMT kit investigating CpGs 74–78 in exon 1 of the MGMT gene by pyrosequencing was used and a cut-off of ≥ 9% for mMGMT was proposed [ ].

Techniques: Selection, Methylation

Journal: Journal of Neuro-Oncology

Article Title: MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing

doi: 10.1007/s11060-026-05633-0

Figure Lengend Snippet: MGMT promoter methylation status and cut-offs. ( a ) Distribution of mean MGMTpm status of all 451 patients. The solid green line representing the supervised cut-off ( b ) and the dashed black line representing the unsupervised cut-off ( c ). Distributions for each individual CpG are presented in Supplementary Fig. . ( b ) Cut-off supervised by OS and adjusted for prognostic factors: age, extent of resection and preoperative ECOG performance status (solid green line), determined through 5-fold cross-validation with the highest concordance index corresponding to the best performing AFT (accelerated failure time) model. ( c ) Bimodal normal mixture model, with unsupervised cut-off (dashed black line) determined as the intersection point of the two distributions. Blue bars represent patients with methylated MGMT and red bars represent patients with unmethylated MGMT, according to the supervised cut-off (solid green line, b )

Article Snippet: A third option is to establish a cut-off based on outcome, such as in the study by Quillien where the Pyromark MGMT kit investigating CpGs 74–78 in exon 1 of the MGMT gene by pyrosequencing was used and a cut-off of ≥ 9% for mMGMT was proposed [ ].

Techniques: Methylation, Biomarker Discovery